Skip Navigation LinksHome > September 2011 - Volume 6 - Issue 5 > A look at HIV journey: from dendritic cells to infection sp...
Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e328349b0a0
Innate immunity: Edited by William A. Paxton and Teunis B.H. Geijtenbeek

A look at HIV journey: from dendritic cells to infection spread in CD4+ T cells

Blanchet, Fabiena; Moris, Arnaudb; Mitchell, John Paula; Piguet, Vincenta

Free Access
Article Outline
Collapse Box

Author Information

aDepartment of Dermatology and Wound Healing, Cardiff University School of Medicine and University Hospital of Wales, Cardiff, Wales, UK

bInstitut National de la Santé et de la Recherche Médicale UMRS945, Université Pierre et Marie Curie Paris-6, Paris, France

Correspondence to Vincent Piguet, Department of Dermatology and Wound Healing, The Welsh Institute of Dermatology, 3rd Floor, Glamorgan House Cardiff University and University Hospital of Wales Heath Park, Cardiff CF14 4XN, Wales, UK Tel: +44 29 20 744721; fax: +44 29 20 744312; e-mail:

Collapse Box


Purpose of review: Dendritic cells and their subsets are among the very first immune cells to tackle incoming pathogens and initiate innate and adaptive immune responses. During the past year, some studies investigating the early events occurring at mucosal sites, upon HIV infection, reinforced our view that the virus has evolved subtle strategies to hijack key cellular components in dendritic cells, thus leading to viral acquisition and dissemination while dampening or delaying antiviral responses.

Recent findings: In this review, we will detail recent research aimed at investigating the involvement of different dendritic cell subtypes on HIV transmission at mucosal sites, the events and cellular factors in dendritic cell guiding HIV trafficking, and polarization at the virological synapse. Furthermore, we will link some of these basic findings with current and novel therapeutic and prophylactic strategies targeting the early events of mucosal HIV transmission.

Summary: It is becoming evident that a better characterization of the early events of HIV transmission and the involvement of dendritic cell subtypes in this process would contribute to strengthen our efforts to improve the current therapeutic and prophylactic strategies.

Back to Top | Article Outline


Pathogen entry at mucosal sites is, most of the time, well controlled and contained in local areas due to the initiation of inflammation and recruitment of immune cells prone to engage in efficient innate immune responses. However, in the case of some pathogens such as HIV, it appears that, once reached, infection establishment and viral spread in the genital subepithelial region benefits from the subversion of mucosa resident cells and from a delayed initiation of an adaptive immune response. During the very early events of HIV infection, the rapid contamination of a founder cell population and the hijacking of immune cells functions leads to viral spread toward lymphoid and nonlymphoid tissues. Among the resident immune cells, whose functions could be diverted, dendritic cell subtypes were suggested to participate in HIV transmission and viral spread [1], as indeed evidenced in vivo with a model of simian immunodeficiency virus (SIV) infection in rhesus macaques [2].

Different dendritic cell subtypes found at mucosal surfaces have been proposed to be involved in HIV transmission to target cells (reviewed in [3,4]). In fact, depending on the cell subtype, the functional presence of innate restriction factors and on the inflammatory or anti-inflammatory state of the environment, viral transfer from dendritic cells to target CD4+ T cells could be significantly altered or enhanced. All recent and past research on the involvement and mechanism of dendritic cell-mediated viral transfer may well be of critical importance to design new topical microbicides and further improve therapeutic strategies.

Back to Top | Article Outline

Early events of viral transmission from mucosal sites

The precise steps of events and cells involved in viral transfer across genital mucosal tissues are now intensively studied and slowly being uncovered (reviewed in [4,5]). Although there is still a lack of information concerning the potential founder population, which could account for infection spread and latency establishment [6], it is well accepted that some of specific cell types present at or directly under mucosal surfaces, such as Langerhans cells, dendritic cells, macrophages, and especially perhaps CD4+ T cells, are known to be very early targets for the virus (Fig. 1). Early events of HIV transmission in humans are quite difficult to look at for obvious reasons, such as timelines from infection to patient sampling or even ethical concerns to get access to human infected samples. For now, simian models of lentiviral infection are still one of the closest means to mimic and extrapolate sequential steps of HIV transmission at the genital mucosa. Such models clearly defined that, although CD4+ cells were among the majority of infected population, dendritic cells might also be infected but more importantly could act as early carriers of virus for local and distal viral transmission (reviewed in [7]). Intriguingly, a subset of dendritic cells, plasmacytoid dendritic cell (pDC), was shown to be highly and rapidly recruited in the challenged tissues and seemingly secreting chemoattractant factors CCL3 and CCL4, involved in the influx of CD4 lymphocytes to the endocervix [8]. Interestingly, pDC enrichment beneath the endocervical epithelium in SIV-infected animals correlated with an increased level of CCL20, the CCR6 ligand, known to induce migration of pDC and T cells into peripheral issues [8]. The local enrichment of CCL20 could stem from vaginal epithelial cells known to secrete this chemokine under pro-inflammatory conditions [9]. Another important contribution of the epithelial/dendritic cell cross-talk could rely on the dramatic increase of thymic stromal lymphopoietin (TSLP) observed in the vaginal tissues within the first 2 weeks after vaginal SIV exposure and paralleling an increase in viral replication [10]. In a human in-vitro model, the increase of TSLP, shown to be directly released following HIV binding on human cervical epithelial cells, was responsible for myeloid dendritic cell (myDC) activation and subsequent increased dendritic cell-mediated HIV-infection of activated CD4+ T cells [10]. Another recent report showed that uterine epithelial cell secretions can decrease DC-SIGN expression on dendritic cell, thus leading to inhibition of dendritic cell-mediated trans-infection of HIV-1 [11]. These data overall highlight the important contribution of structural cells of mucosal surfaces in secreting chemoattractant or soluble factors upon HIV challenge and modulating dendritic cell-mediated viral transmission. Hence, viral transmission in specialized lymphoid tissues could also be modulated by chemokines acting on dendritic cell-mediated HIV trans-infection. As an example, the SDF-1/CXCL12 chemokine, produced from mature dendritic cells (mDCs), was recently shown to inhibit viral propagation to T cells, thus maybe explaining the delayed appearance of X4-tropic viruses [12].

Figure 1
Figure 1
Image Tools
Back to Top | Article Outline

HIV trafficking and transmission from dendritic cell subtypes

Box 1
Box 1
Image Tools

Viruses, such as HIV, can subvert dendritic cell functions to evade immune responses. Interestingly, HIV benefits from specialized endocytic and trafficking cellular pathways in dendritic cells to reach replication-competent CD4+ T cells [3,4]. Efficient HIV transmission to target cells largely depends on the subtype and maturation state of dendritic cell. Whereas immature dendritic cells (imDCs) can capture HIV and support covert infection, mDCs are quite refractory to HIV infection but behave with greater capacity to transfer HIV infectious virions to CD4+ T cells [3,4,13]. Several reports have shown that Lipopolysaccharide-mediated dendritic cell and myDC maturation leads to the clustering of tetraspanin-enriched microdomains (TEMs) wherein HIV virions can localize [14–16]. This tetraspanin-rich compartment, also described in infected macrophages [17], seems dynamic and appears to be connected to the cell surface in both types of cells [16–19]. Even if the TEM is likely to contribute to HIV polarization and transfer toward target cells, the mechanisms underlying formation of this viral docking compartment are still unknown. Another potential important trafficking pathway used by HIV in mDC intersects with the exosome-dissemination pathway for efficient viral transfer [20]. Even if such processes were exacerbated in mDCs, the involvement of the TEMs and the exosome-pathway was also demonstrated for HIV trans-infection stemming from imDCs [14,21]. Maturation of dendritic cells can readily occur upon most microbial invasion and thus could be a means of increased HIV dissemination in lymphoid tissues during pathogenic co-infection. Recent reports showed that the malarial pigment hemozoin can partially mature DC [22] and activate CD4+ T cells, leading to a significant enhancement of dendritic cell-mediated transfer of HIV-1 infection [23]. With previous reports, this is another cumulative evidence of the nefarious effect of pathogen co-infection on dendritic cell subversion and HIV spread.

Back to Top | Article Outline

The virological synapse: a bridge for viral transfer

Efficient viral transfer from dendritic cells to target CD4+ T cells was shown to rely on the formation of a virological synapse (also called infectious synapse) originally reported to concentrate HIV and cognate receptors at the dendritic cell–T-cell contact zone [24]. Virological synapses are cytoskeleton-dependent polarized structures allowing recruitment of virions or viral components at the contact zone between an infected effector cell and a bystander target cell (reviewed in [25]). This type of organized structure could be a means for pathogens to discreetly infect target cells, while hiding from immune system recognition and avoiding efficient antibody neutralization, although, in a context of T cell–T cell virological synapse, it has been recently shown that viral transfer was sensitive to viral entry inhibitors [26]. In comparison with cell-free infection, cell-to-cell pathogen transmission via the virological synapse could potently contribute to infection spread, as recently exemplified by a 1000-fold enhancement of human T lymphotropic virus type-I infection upon cell-to-cell contact [27]. The virological synapse formed between HIV-infected dendritic cells and CD4+ T cells was also demonstrated to be an efficient means for viral spread and it was recently shown that Langerhans cells can rapidly acquire viral particles from apical foreskin keratinocytes and transfer HIV to target T cells at the epidermis–dermis interface of the inner foreskin [28•]. It was shown that HIV acquisition was largely decreased upon circumcision, thus suggesting an important role of the foreskin in HIV transmission. This could consequently imply epithelial Langerhans cell as the main first barrier defense upon HIV challenge. Interestingly, a recent study demonstrated that under pro-inflammatory conditions, Langerhans cells from foreskin inner explants became activated, thus initiating an influx of CD4+ T cells into the epithelial layer and were also more prone to sample environmental factors [29]. As these properties were only apparent with Langerhans cells from the inner but not the outer foreskin, it could be a potential explanation of why and how circumcision decreases HIV transmission [29]. A better characterization and understanding of the mechanisms underlying HIV acquisition and transmission from specific subtypes of Langerhans cell could thus help to develop new strategies to counteract HIV infection in the very early events of viral challenge. For this purpose, the use of cell lines like the Mutz-3 cell lines, shown to phenotypically and functionally behave like human primary Langerhans cells, was proposed to be a suitable model to study the role of Langerhans cells in HIV transmission and to screen potential viral inhibitors [30]. A recent analysis of the spatial architecture of the virological synapse formed between virus-bearing mDCs and T cells proposed that HIV virions sequestered deep within a three-dimensional network of surface-accessible compartments in the dendritic cells are not released passively at the cell–cell contact zone. Indeed, using state-of-the-art imaging technologies (IA-SEM and electron tomography), the authors showed that viral transfer was initiated upon contact of virions localized within surface-accessible membrane invaginations in the dendritic cells with microvillar/filopodial extensions from the T cell [31••]. The transfer of viral particles could also rely on induced actin-based structures stemming from the dendritic cells upon contact with T cells [31••]. In fact, it was shown that HIV was able to induce Cdc42-mediated membrane protrusions rapidly after DC-SIGN engagement by the viral envelope [32]. In this report, the authors clearly demonstrated the presence of HIV-1 on membrane protrusions at the dendritic cell–T-cell interface, thus facilitating infection of contacting CD4+ T cells [32]. These recent findings also contribute to explain the role of DC-SIGN in the formation of the virological synapse. The emergence of new imaging technologies in parallel with the use of adapted genetically modified or fluorescently labeled virions [33] will undoubtedly contribute to a better characterization of virological synapse formation and structure [34].

Back to Top | Article Outline

Dendritic cell-mediated HIV transmission and antiviral innate defenses

Dendritic cells, as one of the very first immune cells to encounter pathogens, behave with broad panoply of antiviral innate effectors and machineries. However, most pathogens have developed potent strategies to facilitate their dissemination while dampening and avoiding antiviral innate immune defenses. HIV has already been shown to subvert and even benefit from activities of cellular factors and machineries mostly involved in cytoskeleton organization, vesicle trafficking, and transcription. Now, it is also becoming evident that HIV has evolved different means to counteract or exploit innate functions in dendritic cells to facilitate viral transmission. Indeed, HIV was shown to benefit from Toll-like receptor 8 (TLR8) and DC-SIGN signaling to replicate in dendritic cells and facilitate dendritic cell-mediated viral transfer to T cells [35••]. Whereas TLR8-mediated NF-κB activation was required for RNA polymerase II (RNAPII)-dependent transcription initiation of integrated provirus, DC-SIGN-mediated Raf-1 signaling was demonstrated to be essential for transcription elongation upon recruitment of pTEF-b to nascent transcripts [35••]. Importantly, pharmacological inhibition of Raf-1 kinase activity prevented dendritic cell-mediated viral transfer [35••]. During the very first events of viral capture, HIV envelop is likely to initiate signaling aimed at altering dendritic cell functions in order for the virus to establish a favorable niche and facilitate dendritic cell-mediated viral transmission. This situation was exemplified recently by the profound dampening of autophagy in dendritic cells upon HIV-1 capture [36•]. This autophagy exhaustion was mediated upon binding of the viral envelope, thus initiating a signaling cascade leading to mammalian Target Of Rapamycin activation, known to antagonize autophagy flux initiation. It was demonstrated that autophagy reduction in dendritic cells correlated with an increase in cell-associated virus and enhanced transfer of HIV infection in-trans from dendritic cells to CD4+ T cells across virological synapse [36•]. Given the multiple roles of the autophagosomal machinery in innate and adaptive responses, this viral-mediated effect was shown to impair dendritic cell-mediated innate and adaptive immune responses.

Although dendritic cells are known to be much less susceptible to productive infection in comparison to CD4+ T cells, an interesting recent report showed that when dendritic cell resistance to infection was circumvented by the presence of Vpx-expressing lentivectors, HIV-1 induced dendritic cell maturation and efficient dendritic cell-mediated innate and adaptive immune responses [37••]. The innate response induced by HIV infection was shown to rely on the activation of the transcription factor Interferon Regulatory Factor 3 upon recognition of newly synthesized HIV-1 capsid by the cellular peptidylprolyl isomerase cyclophilin A (CYPA), and was linked to the restriction of dendritic cell-mediated trans-infection of CD4+ T cells [37••]. These promising data, showing that dendritic cells own a functional intrinsic antiviral machinery, could be of importance for future research areas aimed at elucidating mechanisms of HIV immune escape and transmission.

Among innate antiviral restriction factors, tetherin/BST-2 was shown to antagonize HIV release from infected cells in the absence of Vpu [38]. Its antiviral activity relies on structural determinants and subcellular localization at the viral budding sites rather than sequence specificity or enzymatic activity. This confers a particular interest on the potential involvement of this restriction factor during viral transmission, as already shown in T cell–T cell models of HIV transfer [39–41], and it will, thus, be of importance to decipher any role of tetherin during dendritic cell-mediated transfer of infection to CD4+ T cells.

Maturation of dendritic cells, while restricting HIV replication and subsequently impeding transfer of de-novo produced virions, is known to enhance viral capture and infection of CD4+ T cells in-trans. A recent report demonstrated that the nuclear receptors peroxisome proliferator-activated receptor gamma (PPARγ) and liver X receptor (LXR) once activated, induced a decrease in dendritic cell-associated cholesterol, thus preventing viral capture by dendritic cells and subsequently inhibiting dendritic cell-mediated HIV-1 trans-infection [42].

Back to Top | Article Outline

Potential strategies to block HIV transmission

Several strategies have been developed to try generating efficient vaccines against HIV-1, but, despite recent encouraging results obtained with the RV144 HIV vaccine trial, for now there is a clear lack of efficient prophylactic vaccines. Alternative strategies have emerged, with the use of microbicides, aimed at targeting and preventing specific steps of viral transmission upon mucosal surfaces challenge by HIV-1 (reviewed in [43]). Targeting steps involving dendritic cell-mediated HIV transmission are gaining recognition, as this would occur during the very first event of viral challenge. Recent candidate microbicides, like PRO2000, were shown to potently block dendritic cell-mediated HIV transfer and infection in the highly permissive dendritic cell-T-cell environment [44]. Microbicidal agents can be designed to target viral or cellular components and, recently, entry inhibitors targeting the viral envelope (BMS-C and T-1249) or CCR5 (CMPD167) at the surface of dendritic cell were proven to efficiently block HIV infection in dendritic cell–T-cell co-cultures [45]. However, a clear proof of concept was still required to demonstrate the efficiency of microbicide to abrogate HIV transmission in humans. For the first time, the potential use of a microbicide-based prophylactic strategy was convincingly demonstrated in a recent report, from the CAPRISA 004 trial, showing that a 1% tenofovir-based gel could prevent HIV acquisition in women by almost 40% [46••]. This preventive effect was even shown to reach 54% when gel adherence was optimal (>80%) [46••]. Even if the cell type(s) targeted by the microbicide were not characterized, this study offers a clear breakthrough in the field of antiviral gel-based microbicides in humans to block the early events of HIV transmission. Another compound based on a hybrid Syndecan–Fc molecule, hypothesized to target a highly conserved Arg298 in the V3 region of gp120, was shown to exert a potent antiviral activity against a broad range of viral isolates and to profoundly block dendritic cell-mediated HIV transfer to CD4+ T cells [47].

As HIV gets access to the host mainly through mucosal surfaces, inducing a strong and potent mucosal immunity to HIV might hopefully stop the establishment of early HIV infection, and transmission to CD4+ T cells. In nonhuman primates, Bomsel et al.[48••] recently reported that intranasal immunization with HIVgp41 induced mucosal antibodies providing protection against repeated low-dose intravaginal challenges. In vitro, the authors further demonstrated that mucosal antibodies could neutralize HIV and also block HIV transcytosis through epithelial cell monolayers [48••]. Several strategies are currently being developed to induce sterilizing humoral and/or T-cell immunity at mucosal sites. Vaccine carriers include DNA, antibodies, nanoparticles, virus-like particles, or viral vectors. Most of these strategies are designed to facilitate the uptake of HIV antigens by antigen presenting cells. Viral vectors, and to a lesser extent virus-like particles, trigger innate immunity that can potentially provide a natural adjuvant effect. For instance, modified vaccinia virus ankara (MVA), a nonpersisting vector with excellent safety records, triggers innate sensors such as TLRs and NALP3 inflammasome leading to chemokines, IFN-β and IL-1β secretions [49]. MVA has a very large tropism including epithelial cells, lung fibroblasts, pulmonary, and bronchial cells [50•]. Hence, dendritic cells can capture MVA-infected cells that express HIV antigens to activate HIV-specific CD8+ and CD4+ T cells [50•]. Recombinant antibodies directed to dendritic cell surface receptors such as lectins (Dendritic and Epithelial Cell-205, DC-SIGN...) also offer a chance to supply HIV antigen to dendritic cells [51,52]. However, an increasing number of human dendritic cell subsets with distinct capacity to prime cellular or humoral immune responses are being recognized. Thereafter, a better understanding of the biology of the dendritic cell subsets will be necessary to design dendritic cell-based vaccines for HIV [53].

Mucosal intrinsic antiviral immunity might also confer some degree of protection upon viral encounter. Following mucosal immunization of nonhuman primates, two recent studies reported upregulation of the antiviral factor APOBEC-3G (A3G) in CCR5+CD4+ memory T cells [54] and mucosal dendritic cells or CD14+ cells [55••]. Upregulation of A3G mRNA was maintained for several weeks after immunization. Remarkably, upon SIV challenge, A3G mRNA upregulation correlated inversely with viral loads suggesting that A3G upregulation provided an antiviral effect. Although the correlation between A3G expression and antiviral effect was observed in different cell types in these studies, due probably to the use of different vaccine adjuvants, they provide the first evidence that mucosal immunization triggers an innate signature reminiscent of a memory response. Although the exact mechanism underlying A3G correlation with protection from SIV infection is not clear, it might be due to the action of A3G on HIV replication [56] or on the generation of Major Histocompatibility Complex-I-restricted HIV antigen and HIV-specific T-cell activation [57•].

Therapeutic vaccines might also be used to boost immune responses against HIV to eliminate residual viral replication and eradicate reservoirs or to reduce drug regimens on HAART. However, a major drawback would be to create a milieu facilitating HIV replication and spread. Illustrating this issue, a greater viral rebound and reduced time to resume antiretroviral therapy was observed after therapeutic immunization with an ALVAC-HIV vaccine [58]. Indeed, it was shown recently that virus rebound upon vaccination was associated with an increased activation of HIV-specific CD4(+) T cells [59], known to be preferential targets of viral transmission and infection [60,61]. A thorough characterization of the interactions between vaccine candidates, HIV and cells of the immune system, especially dendritic cells, will be probably required. MVA, for instance, has been shown in vitro to abolish HIV transfer from dendritic cells to activated T cells probably due to IFN-α secretions [50•].

Back to Top | Article Outline


As dendritic cells and their subsets have altered cellular and immune functions following HIV infection, these cells are likely to be excellent targets for future vaccine and prophylactic strategies aimed at abrogating viral infection and spread to CD4+ T cells. However, a better characterization of the early events of HIV trafficking and impact on dendritic cell functions would enable us to refine future immunotherapeutic strategies aimed at improving immunogenicity and dendritic cell-mediated antiviral responses.

Hence, improvement of available in-vitro human mucosal or ex-vivo organ culture models and the use of new animal models to study the very early events of HIV transmission will undoubtedly contribute to better characterization of immune components sufficient in preventing HIV-1 transmission and to development of efficient therapeutic and prophylactic strategies.

Back to Top | Article Outline


The present work was supported by a Swiss National Science Foundation (SNF) grant and a Global Health Grant from the Gates foundation to V.P., as well as program and project grants from Agence Nationale de Recherche sur le SIDA (ANRS) and SIDACTION for A.M.

Back to Top | Article Outline
Conflicts of interest

There are no conflicts of interest.

Back to Top | Article Outline

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

* • of special interest

* •• of outstanding interest

Additional references related to this topic can also be found in the Current World Literature section in this issue (pp. 446–447).

Back to Top | Article Outline


1. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217–223.

2. Hu J, Gardner MB, Miller CJ. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 2000; 74:6087–6095.

3. Cunningham AL, Donaghy H, Harman AN, et al. Manipulation of dendritic cell function by viruses. Curr Opin Microbiol 2010; 13:524–529.

4. Piguet V, Steinman RM. The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol 2007; 28:503–510.

5. Hladik F, McElrath MJ. Setting the stage: host invasion by HIV. Nat Rev Immunol 2008; 8:447–457.

6. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127–139.

7. Turville SG, Peretti S, Pope M. Lymphocyte-dendritic cell interactions and mucosal acquisition of SIV/HIV infection. Curr Opin HIV AIDS 2006; 1:3–9.

8. Li Q, Estes JD, Schlievert PM, et al. Glycerol monolaurate prevents mucosal SIV transmission. Nature 2009; 458:1034–1038.

9. Cremel M, Berlier W, Hamzeh H, et al. Characterization of CCL20 secretion by human epithelial vaginal cells: involvement in Langerhans cell precursor attraction. J Leukoc Biol 2005; 78:158–166.

10. Fontenot D, He H, Hanabuchi S, et al. TSLP production by epithelial cells exposed to immunodeficiency virus triggers DC-mediated mucosal infection of CD4+ T cells. Proc Natl Acad Sci U S A 2009; 106:16776–16781.

11. Ochiel DO, Ochsenbauer C, Kappes JC, et al. Uterine epithelial cell regulation of DC-SIGN expression inhibits transmitted/founder HIV-1 trans infection by immature dendritic cells. PLoS One 2010; 5:e14306.

12. Gonzalez N, Bermejo M, Calonge E, et al. SDF-1/CXCL12 production by mature dendritic cells inhibits the propagation of X4-tropic HIV-1 isolates at the dendritic cell–T-cell infectious synapse. J Virol 2010; 84:4341–4351.

13. Wang JH, Janas AM, Olson WJ, Wu L. Functionally distinct transmission of human immunodeficiency virus type 1 mediated by immature and mature dendritic cells. J Virol 2007; 81:8933–8943.

14. Garcia E, Pion M, Pelchen-Matthews A, et al. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. Traffic 2005; 6:488–501.

15. Izquierdo-Useros N, Blanco J, Erkizia I, et al. Maturation of blood-derived dendritic cells enhances human immunodeficiency virus type 1 capture and transmission. J Virol 2007; 81:7559–7570.

16. Yu HJ, Reuter MA, McDonald D. HIV traffics through a specialized, surface-accessible intracellular compartment during trans-infection of T cells by mature dendritic cells. PLoS Pathog 2008; 4:e1000134.

17. Deneka M, Pelchen-Matthews A, Byland R, et al. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol 2007; 177:329–341.

18. Cavrois M, Neidleman J, Kreisberg JF, Greene WC. In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions. PLoS Pathog 2007; 3:e4.

19. Garcia E, Nikolic DS, Piguet V. HIV-1 replication in dendritic cells occurs through a tetraspanin-containing compartment enriched in AP-3. Traffic 2008; 9:200–214.

20. Izquierdo-Useros N, Naranjo-Gomez M, Archer J, et al. Capture and transfer of HIV-1 particles by mature dendritic cells converges with the exosome-dissemination pathway. Blood 2009; 113:2732–2741.

21. Wiley RD, Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 2006; 103:738–743.

22. Diou J, Tardif MR, Barat C, Tremblay MJ. Dendritic cells derived from hemozoin-loaded monocytes display a partial maturation phenotype that promotes HIV-1 trans-infection of CD4+ T cells and virus replication. J Immunol 2010; 184:2899–2907.

23. Diou J, Tardif MR, Barat C, Tremblay MJ. Malaria hemozoin modulates susceptibility of immature monocyte-derived dendritic cells to HIV-1 infection by inducing a mature-like phenotype. Cell Microbiol 2010; 12:615–625.

24. McDonald D, Wu L, Bohks SM, et al. Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science 2003; 300:1295–1297.

25. Mothes W, Sherer NM, Jin J, Zhong P. Virus cell-to-cell transmission. J Virol 2010; 84:8360–8368.

26. Martin N, Welsch S, Jolly C, et al. Virological synapse-mediated spread of human immunodeficiency virus type 1 between T cells is sensitive to entry inhibition. J Virol 2010; 84:3516–3527.

27. Mazurov D, Ilinskaya A, Heidecker G, et al. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. PLoS Pathog 2010; 6:e1000788.

28•. Ganor Y, Zhou Z, Tudor D, et al. Within 1h, HIV-1 uses viral synapses to enter efficiently the inner, but not outer, foreskin mucosa and engages Langerhans-T cell conjugates. Mucosal Immunol 2010; 3:506–522.

This study analyses the very early events of HIV transmission using ex-vivo foreskin explants and in-vitro reconstructed immunocompetent foreskins and shows that HIV-1 transmission is most efficient from the inner, but not outer, foreskin leading to Langerhans cell-mediated HIV transfer to T cells at the epidermis-dermis interface.

29. Fahrbach KM, Barry SM, Anderson MR, Hope TJ. Enhanced cellular responses and environmental sampling within inner foreskin explants: implications for the foreskin's role in HIV transmission. Mucosal Immunol 2010; 3:410–418.

30. de Jong MA, de Witte L, Santegoets SJ, et al. Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors. J Leukoc Biol 2010; 87:637–643.

31••. Felts RL, Narayan K, Estes JD, et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A 2010; 107:13336–13341.

This study describes the spatial architecture of virological synapse formed between mDCs and T cells and shows that HIV cell-to-cell transmission requires filopodial extensions emanating from CD4+ T cells, which make contact with HIV virions sequestered deep within a three-dimensional network of surface-accessible compartments in the dendritic cells.

32. Wang JH, Wells C, Wu L. Macropinocytosis and cytoskeleton contribute to dendritic cell-mediated HIV-1 transmission to CD4+ T cells. Virology 2008; 381:143–154.

33. Nikolic DS, Lehmann M, Felts R, et al. HIV-1 activates Cdc42 and induces membrane extensions in immature dendritic cells to facilitate cell-to-cell virus propagation. Blood 2011 doi: 10.1182/blood-2010-09-305417.

34. Dale B, McNerney GP, Thompson DL, et al. Visualizing cell-to-cell transfer of HIV using fluorescent clones of HIV and live confocal microscopy. J Vis Exp 2010 Oct 7; (44).

35••. Gringhuis SI, van der Vlist M, van den Berg LM, et al. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010; 11:419–426.

This study demonstrates that HIV can induce both TLR8-mediated RNAPII activation and DC-SIGN/Raf-1 signaling to initiate integrated provirus transcription and to promote nascent transcripts elongation, respectively.

36•. Blanchet FP, Moris A, Nikolic DS, et al. Human immunodeficiency virus-1 inhibition of immunoamphisomes in dendritic cells impairs early innate and adaptive immune responses. Immunity 2010; 32:654–669.

This study shows that HIV capture by dendritic cells induces a rapid shutdown of autophagy flux subsequently to HIV envelop-dependent mTOR activation and links HIV-mediated autophagy exhaustion to early impaired dendritic cell immune functions.

37••. Manel N, Hogstad B, Wang Y, et al. A cryptic sensor for HIV-1 activates antiviral innate immunity in dendritic cells. Nature 2010; 467:214–217.

This study demonstrates that, due to low levels of infection in dendritic cells, HIV can escape from a CYPA-dependent cell-intrinsic sensor, which could promote and sustain efficient dendritic cell-mediated antiviral innate and adaptive immune response.

38. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451:425–430.

39. Casartelli N, Sourisseau M, Feldmann J, et al. Tetherin restricts productive HIV-1 cell-to-cell transmission. PLoS Pathog 2010; 6:e1000955.

40. Jolly C, Booth NJ, Neil SJ. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells. J Virol 2010; 84:12185–12199.

41. Kuhl BD, Sloan RD, Donahue DA, et al. Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology 2010; 7:115.

42. Hanley TM, Blay Puryear W, Gummuluru S, Viglianti GA. PPARgamma and LXR signaling inhibit dendritic cell-mediated HIV-1 capture and trans-infection. PLoS Pathog 2010; 6:e1000981.

43. Nikolic DS, Piguet V. Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission. J Invest Dermatol 2009; 130:352–361.

44. Teleshova N, Chang T, Profy A, Klotman ME. Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer. Antimicrob Agents Chemother 2008; 52:1751–1758.

45. Frank I, Robbiani M. Attachment and fusion inhibitors potently prevent dendritic cell-driven HIV infection. J Acquir Immune Defic Syndr 2011; 56:204–212.

46••. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168–1174.

This proof-of-concept study demonstrates that gel-based microbicide can potently decrease HIV acquisition in humans. The authors, reporting data from the CAPRISA 004 trial, show that a 1% tenofovir gel microbicide could prevent HIV infection in women having sex by 39% and even reaching 54% when gel adherence was optimal.

47. Bobardt MD, Chatterji U, Schaffer L, et al. Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agent. Antimicrob Agents Chemother 2010; 54:2753–2766.

48••. Bomsel M, Tudor D, Drillet AS, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal Simian-Human Immunodeficiency Virus challenges. Immunity 2011; 34:269–280.

A very nice demonstration using nonhuman primates that intranasal vaccination with HIVgp41-subunit antigens grafted on virosomes generates antigp41 mucosal IgA and IgG responses and protection from SHIV challenge. Vaginal IgA and IgG exhibited HIV transcytosis-blocking and neutralizing activities, respectively.

49. Delaloye J, Roger T, Steiner-Tardivel QG, et al. Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome. PLoS Pathog 2009; 5:e1000480.

50•. Brandler S, Lepelley A, Desdouits M, et al. Preclinical studies of a modified vaccinia virus Ankara-based HIV candidate vaccine: antigen presentation and antiviral effect. J Virol 2010; 84:5314–5328.

This study provides a thorough characterization of a new MVA-based HIV vaccine, focusing on its tropism for primary human cells, its cytopathic effect, its antigenicity, and its ability to generate an antiviral state in dendritic cell/T cell co-cultures.

51. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci U S A 2011; 108:2384–2389.

52. Nchinda G, Amadu D, Trumpfheller C, et al. Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc Natl Acad Sci U S A 2010; 107:4281–4286.

53. Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464–478.

54. Wang Y, Bergmeier LA, Stebbings R, et al. Mucosal immunization in macaques upregulates the innate APOBEC 3G antiviral factor in CD4(+) memory T cells. Vaccine 2009; 27:870–881.

55••. Sui Y, Zhu Q, Gagnon S, et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A 2010; 107:9843–9848.

Together with the work of Wang et al. (ref. 54), this study describes that vaccination against SIV combined with adjuvants (IL-15 + TLR agonists) drives an innate immune response characterized by long-lasting APOBEC-3G expression in SIV target cells. They show that APOBEC-3G expression in mucosal dendritic cells and CD14+ cells correlates with lower viral loads.

56. Stalder R, Blanchet F, Mangeat B, Piguet V. Arsenic modulates APOBEC3G-mediated restriction to HIV-1 infection in myeloid dendritic cells. J Leukoc Biol 2010; 88:1251–1258.

57•. Casartelli N, Guivel-Benhassine F, Bouziat R, et al. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J Exp Med 2010; 207:39–49.

This study unravels a novel function for APOBEC-A3G, acting not only as an intrinsic antiviral factor, but also as an inducer of HIV-specific Cytotoxic T Lymphocytes activation, thus linking innate and adaptive immunity.

58. Autran B, Murphy RL, Costagliola D, et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008; 22:1313–1322.

59. Papagno L, Alter G, Assoumou L, et al. Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 2011; 25:27–36.

60. Douek DC, Brenchley JM, Betts MR, et al. HIV preferentially infects HIV-specific CD4+ T cells. Nature 2002; 417:95–98.

61. Moris A, Pajot A, Blanchet F, et al. Dendritic cells and HIV-specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood 2006; 108:1643–1651.


CD4+ T cells; dendritic cells; HIV; microbicide; transmission; virological synapse

© 2011 Lippincott Williams & Wilkins, Inc.


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.